CRISPR-Cas9 Breakthrough: CTX310 Delivers Sustained Lipid Control for Dyslipidemia in Phase 1a Trial, Published in NEJM

September 6, 2026

The New England Journal of Medicine USA

Overview

CRISPR Therapeutics’ CTX310, a novel CRISPR-Cas9 gene-editing therapy, has demonstrated sustained and profound reductions in key lipid markers—angiopoietin-like 3 (ANGPTL3), triglycerides, and LDL cholesterol—over a full year in patients with dyslipidemia. Published in ‘The New England Journal of Medicine,’ the Phase 1a trial results validate the potential of in vivo liver gene editing for durable therapeutic effects. This milestone promises a significant advance in hyperlipidemia treatment by offering a potentially foundational solution with a favorable tolerability profile.

In Depth

Background

Hypertriglyceridemia and elevated LDL cholesterol represent significant global public health challenges, being major risk factors for cardiovascular disease. While conventional pharmacological treatments, including statins, PCSK9 inhibitors, and fibrates, are widely used and effective, a subset of patients—particularly those with severe genetic dyslipidemias—struggle to achieve adequate lipid control or face a lifelong burden of daily medication. In vivo gene-editing therapies like CTX310 are emerging as a potentially foundational, even curative, solution to address these persistent challenges.

Targeting angiopoietin-like 3 (ANGPTL3) is a strategic approach in lipid metabolism, as it influences multiple lipid pathways, offering the potential for comprehensive improvements in lipid profiles. CRISPR-Cas9 technology, celebrated for its high specificity and efficiency in gene editing, is rapidly finding applications across various genetic diseases. The publication of these findings in ‘The New England Journal of Medicine’ further solidifies its international clinical validation. The competitive landscape for in vivo gene editing is active, with other therapies such as Intellia Therapeutics’ Nex-z (for TTR amyloidosis) and Verve Therapeutics’ VERVE-101 (for familial hypercholesterolemia) also under development.

Key Findings

One-year follow-up results from the Phase 1a clinical trial of CRISPR Therapeutics’ pioneering CRISPR-Cas9 gene-editing therapy, CTX310, were recently published in ‘The New England Journal of Medicine’. This landmark report details that a single intravenous infusion of CTX310 achieved profound and sustained reductions in key lipid markers—angiopoietin-like 3 (ANGPTL3), triglycerides, and LDL cholesterol—over a 12-month period in patients diagnosed with hyperlipidemia.

Specifically, the study reported an average reduction of approximately 80-90% in serum ANGPTL3 levels from baseline across all treated subjects. This significant decrease in ANGPTL3 was directly correlated with a robust and sustained reduction in both triglycerides and LDL cholesterol. Critically, CTX310 demonstrated a favorable safety and tolerability profile throughout the one-year follow-up, with no serious adverse events or unexpected off-target editing concerns reported. These findings strongly validate the potential of in vivo gene editing to deliver a durable and transformative therapeutic effect for intractable dyslipidemias, leveraging a single administration to achieve potent, long-lasting effects for chronic conditions.

Mechanism of Action

CTX310 is an advanced in vivo CRISPR-Cas9 gene-editing therapeutic engineered to permanently inactivate the expression of the ANGPTL3 gene within hepatocytes (liver cells). ANGPTL3 plays a crucial role as a regulator of lipid metabolism; individuals with naturally occurring loss-of-function mutations in this gene are known to exhibit significantly low levels of triglycerides and LDL cholesterol. CTX310 employs an adeno-associated virus (AAV) vector system to efficiently deliver the CRISPR-Cas9 components—specifically the Cas9 nuclease and a precisely designed guide RNA—to the target liver cells. This targeted delivery facilitates accurate editing of the ANGPTL3 genomic locus, thereby silencing its expression and subsequently reducing circulating ANGPTL3 protein levels.

Strategic Significance & Outlook

The compelling one-year follow-up data from the CTX310 Phase 1a trial provide strong evidence that in vivo gene editing holds transformative potential for the treatment of dyslipidemias. The observed sustained and profound lipid-lowering effects could profoundly reduce cardiovascular disease risk, representing a groundbreaking therapeutic option, especially for patients who have not achieved adequate control with existing pharmacological interventions.

CRISPR Therapeutics is anticipated to advance CTX310 into larger Phase 2 and subsequently Phase 3 clinical trials, moving closer to regulatory approval. This early success could serve as a powerful catalyst for the broader application of in vivo gene-editing technology, extending its reach beyond cardiovascular metabolic diseases to a wider spectrum of genetic disorders. The integration of this sophisticated technology into routine clinical practice and its profound impact on patient outcomes will be closely monitored over the coming years. Continued rigorous evaluation of the long-term safety profile, including any potential off-target editing risks, will remain a critical focus for ensuring widespread adoption and patient trust.

Source: https://crisprmedicinenews.com/news/clinical-single-crispr-infusion-keeps-lipids-low-for-a-year/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.